Compare Goldman Sachs Group Inc (GS) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Goldman Sachs Group Inc vs Merck & Co., Inc. — how do they compare? Goldman Sachs Group Inc trades at $1,141.67 (market cap $339.87B), while Merck & Co., Inc. trades at $125.19 (market cap $305.29B). The key difference: Goldman Sachs Group Inc and Merck & Co., Inc. are close in size by market cap, and Merck & Co., Inc. pays the higher dividend (2.75%). Which is the better fit depends on your goals.
| GS | MRK | |
|---|---|---|
Market Cap | $339.87B | $305.29B |
Volume | 2,592,735 | — |
Sector | Financials | Health |
52-Week High | $1.15K | $129.52 |
52-Week Low | $700.41 | $77.60 |
Dividend Yield | 1.56% | 2.75% |
Enterprise Value | — | $348.71B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Goldman Sachs (GS) trades at $1,140, up 9.0% over 24 hours, with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with Q2 2026 EPS beating expectations at $20.98 versus $14.47, and revenue growth from $58.28B in 2025 to $60.4B projected for 2026. Recent news highlights Goldman's role in leading high-profile IPOs including Anthropic, signaling strong investment banking pipeline strength.
Outlook remains positive with analyst consensus price target of $1,140K and 40% buy ratings, though RSI levels suggest potential near-term overbought conditions. Key risks include volatile cash flow patterns and high leverage, while institutional sentiment supports continued growth from M&A activity and AI-driven market opportunities.
Merck (MRK) trades at $120.80, down 2.6% on the day, with technical indicators showing a bullish moving average signal but neutral oscillators. The company reported strong recent earnings beats and maintains solid profitability with a 73.91% gross margin and 13.59% net margin. Recent news highlights Merck's acquisition of Terns Pharmaceuticals for approximately $6.7 billion to bolster its oncology pipeline, while institutional investors continue accumulating shares.
The outlook remains positive with analyst consensus at Buy (67.57%) and a $137.30 price target, suggesting 13.7% upside. Key risks include integration challenges from the Terns acquisition, competitive pressures in oncology, and potential regulatory headwinds. Strong cash flow generation ($16.47B operating cash flow in 2025) supports continued dividend payments and strategic investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Goldman Sachs Group Inc
The Goldman Sachs Group, Inc., a bank holding company, is a global investment banking and securities firm specializing in investment banking, trading and principal investments, asset management and securities services. The Company provides services to corporations, financial institutions, governments, and high-net worth individuals.
Read more on GS →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
